RxSight Q3 revenue $12.6M (+118% YoY); raises FY22 guidance to $47-48M

RxSight, Inc.

2022-Q3 EPS reported -$1.86 revenue$32,917,000

Q3 2022 revenue of $12.6M, up 118% YoY; LDD installed base reached 343 units (113% YoY increase).
Sold 6,595 LALs (+234% YoY); gross margin improved to 42.5% vs 23.2% in Q3 2021.
Raised FY2022 revenue guidance to $47-48M (from $44-46M); gross margin guidance raised to 41-43%.
Net loss of $(16.8)M or $(0.61)/share vs $(12.7)M or $(0.68)/share in Q3 2021.
Cash & investments $112.8M; long-term debt $40.0M; operating expense guidance lowered.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

RxSight, Inc. reported three and nine months ended September 30, 2022 results: revenue $12.6 million, net income $(16.8) million, EPS $(0.61) per basic and diluted share. Guidance raised.

Period: three and nine months ended September 30, 2022
Revenue: $12.6 million
Net income: $(16.8) million
EPS: $(0.61) per basic and diluted share
Guidance: raised
Result: reported results

Exact text from the filing

cataract surgery, today reported financial results for the three and nine months ended September 30, 2022. Key Quarterly Highlights: • Delivered third quarter 2022 revenue of $12.6 million, an increase of 118% compared to the third quarter of 2021, reflecting: • The sale of 49 Light Delivery Devices (LDDTMs), representing a 58% unit increase from the third quarter

View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.